Hepatitis Forums
Hepatitis B Main Forums => Hepatitis B => Topic started by: Hep Editors on June 15, 2018, 10:37:51 am
-
An experimental hepatitis B virus (HBV) treatment, the core protein allosteric modulator RO7049389, showed robust activity against the virus and was safe and well tolerated, MedPage Today reports. These findings support further study of the agent as a possible component of a hep B cure regimen.
Presenting their findings at the 52nd International Liver Congress in Paris, researchers conducted a two-part study of RO7049389. The first part examined the safety, tolerability and pharmacokinetics (how the drug is metabolized) of the agent. The second part gave a variety of single doses of the drug, ranging from 150 to 2,000 milligrams, to five groups of people as well as multiple doses, ranging from 200 to 800 mg, to another five groups of people who did not have hep B. The second part of the study also gave twice daily doses of 200 mg of RO7049389 for 28 days to individuals with chronic hep B who had not been treated before.
Read more...
https://www.hepmag.com/article/early-trial-experimental-hepatitis-b-agent-sets-stage-cure-research